Argo Biopharma Receives FDA Fast Track Designation for BW-20805, an Investigational siRNA Therapy for the Treatment of HAE

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted ...

Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of ...
Healio

Navenibart safe, lowers hereditary angioedema attack rate up to 24 months

Among adults with hereditary angioedema, the safety of navenibart up to 24 months was favorable, according to interim trial ...
NC Biotech

BioCryst advances pediatric HAE treatment as new CEO takes the helm

Durham-based BioCryst Pharmaceuticals Inc. is advancing care for children living with hereditary angioedema (HAE) as it ...
WebMD

Preventing Hereditary Angioedema Attacks With Takhzyro

Takhzyro (lanadelumab-flyo) is a biologic medicine used to prevent hereditary angioedema (HAE) attacks in people who are 2 years or older. During an HAE attack, swelling under the skin happens in ...
Rutland Herald

New study for people with hereditary angioedema

(BPT) - In the U.S., about 7,000 people live with hereditary angioedema, or HAE, 1,2 a rare condition that results in unpredictable swelling attacks. 3-8 Symptoms often appear early in life and can ...
MarketWatch

BioCryst to Present New HAE Data from ORLADEYO(R) (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

The MarketWatch News Department was not involved in the creation of this content. RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today ...
Medical News Today

You ask, we answer: When is hereditary angioedema (HAE) an emergency?

A person with hereditary angioedema (HAE) should seek emergency care during an HAE episode if they are having difficulty breathing or experiencing swelling of the tongue or throat, which could lead to ...
Business Insider

ADARx Pharmaceuticals Presents Onvuzosiran Data Supporting Potential for Sustained Attack-Free Rates with Reduced Treatment Burden in Patients with HAE

– Onvuzosiran achieved significant and durable reductions of plasma kallikrein levels with a favorable safety profile in Phase 1/2 – – Positive results support ongoing Phase 3 clinical trial – SAN ...

Pharvaris N.V.: Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAP ...
Nasdaq

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary ...